The Food and Drug Administration last week authorized emergency use for a non-invasive nerve stimulator at home or in health care settings to treat suspected COVID-19 patients experiencing worsened asthma-related shortness of breath and reduced airflow. The device from electroCore, Inc. is intended for use when other drug therapies are not tolerated or do not provide enough symptom relief. FDA also authorized as a ventilator a CPAP mask combined with a N95 from Circadiance.

Related News Articles

Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…